Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Michael D Deel

Assistant Professor of Pediatrics
Pediatrics, Hematology-Oncology
Duke University, Box 102382, Durham, NC 27710
Duke University Medical Center, Box 102382, Durham, NC 27710

Selected Publications


Pediatric spindle cell/sclerosing rhabdomyosarcoma with FUS-TFCP2 fusion: a case report and literature review.

Journal Article Transl Pediatr · January 29, 2024 BACKGROUND: FUS-TFCP2 gene fusion is a recently identified and highly distinct molecular subtype of spindle cell/sclerosing rhabdomyosarcoma (RMS), with fewer than 40 cases being reported to date. Due to its low incidence, clinical studies on this subtype ... Full text Link to item Cite

Hematology of childhood and adolescence

Chapter · January 1, 2023 Hematologic homeostasis requires an intricate interaction of red blood cells, white blood cells, platelets, and coagulation factors. Normal parameters vary with age, sex, and race. Underlying causes for hematologic abnormalities in children may range from ... Full text Cite

Oncology of childhood and adolescence

Chapter · January 1, 2023 Childhood and adolescent cancer are broadly categorized into leukemia, lymphoma, extracranial solid tumors, and central nervous system (CNS) tumors. Many of these cancers can present as oncologic emergencies, which are important to recognize. Supportive ca ... Full text Cite

More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma.

Journal Article J Pediatr Hematol Oncol · August 1, 2021 Malignant ectomesenchymoma (MEM) is a rare multiphenotypic tumor comprised of mesenchymal and neuroectodermal components. MEM is typically diagnosed in infants and younger children and outcomes are variable. The current approach for treating MEM includes t ... Full text Link to item Cite

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.

Journal Article J Clin Med · April 1, 2021 Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children's Oncology Group (COG) convened a rhabdomyosarcoma n ... Full text Link to item Cite

Advances in the Diagnosis and Management of Neonatal Sarcomas.

Journal Article Clin Perinatol · March 2021 Neonatal sarcomas comprise a heterogeneous group of rare soft tissue neoplasms that present unique diagnostic and therapeutic challenges. Recent advances in molecular profiling have improved diagnostic capabilities and reveal novel therapeutic targets. Cli ... Full text Link to item Cite

A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling.

Journal Article Biol Open · February 9, 2021 Featured Publication The development of three-dimensional cell culture techniques has allowed cancer researchers to study the stemness properties of cancer cells in in vitro culture. However, a method to grow PAX3-FOXO1 fusion-positive rhabdomyosarcoma (FP-RMS), an aggressive ... Full text Link to item Cite

Advances in the management of pediatric genitourinary rhabdomyosarcoma.

Journal Article Transl Androl Urol · October 2020 Recent clinical trials have revealed several unanticipated complexities in the optimal management of genitourinary rhabdomyosarcoma (RMS). Improvement in outcomes for low- and intermediate-risk RMS over the past several decades led to the design of clinica ... Full text Open Access Link to item Cite

Abstract 3882: YAP1 and WWTR1 (TAZ) positively regulate PAX3-FOXO1 transcriptional programming in fusion-positive rhabdomyosarcoma

Conference Cancer Research · August 15, 2020 AbstractAlthough more than 20 years have passed since the discovery that fusion-positive rhabdomyosarcoma (FP-RMS) is driven by the chimeric fusion oncogene PAX3-FOXO1 (P3F), therapeutically tractable compon ... Full text Cite

RASSF4 is required for skeletal muscle differentiation.

Journal Article Cell Biol Int · February 2020 Featured Publication RASSF4, a member of the classical RASSF family of scaffold proteins, is associated with alveolar rhabdomyosarcoma, an aggressive pediatric cancer of muscle histogenesis. However, the role of RASSF4 in normal myogenesis is unknown. We demonstrate here that ... Full text Link to item Cite

Abstract 3670: Transcriptional co-activators TAZ/YAP are novel regulators of PAX3-FOXO1 transcriptional programing and fusion-positive rhabdomyosarcoma cancer cell stemness

Conference Cancer Research · July 1, 2019 AbstractIntroduction: Fusion Positive Rhabdomyosarcoma (FP-RMS), a soft tissue sarcoma of adolescents and young adults, is driven by the oncogenic transcription factor PAX3-FOXO1 (P3F). Although most patient ... Full text Cite

The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.

Journal Article Clin Cancer Res · June 1, 2018 Purpose: Alveolar rhabdomyosarcoma (aRMS) is a childhood soft tissue sarcoma driven by the signature PAX3-FOXO1 (P3F) fusion gene. Five-year survival for aRMS is <50%, with no improvement in over 4 decades. Although the transcriptional coactivator TAZ is o ... Full text Link to item Cite

A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Journal Article Front Oncol · 2015 The Hippo signaling pathway is an evolutionarily conserved developmental network vital for the regulation of organ size, tissue homeostasis, repair and regeneration, and cell fate. The Hippo pathway has also been shown to have tumor suppressor properties. ... Full text Open Access Link to item Cite

Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children.

Journal Article Pediatr Blood Cancer · December 2013 BACKGROUND: Recent studies reviewing immune mechanisms of immune thrombocytopenia (ITP) have suggested acute and chronic forms may represent distinct immunopathological disorders. This study evaluated absolute lymphocyte counts (ALCs) as predictors for ITP ... Full text Link to item Cite